Estrogen priming of breast cancer ZR-75-1 cells results in a unique response to a timecourse of progesterone and medroxyprogesterone acetate exposure

A timecourse assessment of the response of ZR-75-1 breast cancer cells to progestogens in cells pretreated with estrogen. P4 treatment in cells pretreated with E2 results in a unique transcriptional response, including upregulation of ErbB growth factor pathways and alteration of the intrinsic subtype of the breast cancer cells.

44